Can a positron emission tomography (PET) scan detect endometriosis in a female patient of reproductive age and is there a novel drug that can illuminate endometriosis on a scan?

PET Scan Detection of Endometriosis and Novel Radiopharmaceutical Agents

Can Standard PET Scans Detect Endometriosis?

Standard FDG-PET/CT can detect endometriosis but has significant limitations and is not recommended as a diagnostic imaging modality for this condition. 1

Performance Characteristics of FDG-PET/CT

• FDG-PET/CT demonstrates inconsistent uptake in endometriotic lesions, with a patient-based detection rate of only 62% in women with confirmed endometriosis 2
• On a per-lesion basis, FDG-PET/CT detects only 55% of endometriotic sites, with SUVmax values ranging from 1.8 to 5.3 (median 3.8) 2
• The low and variable metabolic activity of endometriotic lesions means many lesions will be missed on standard FDG-PET imaging 2

Critical Timing Considerations

• PET/CT acquisition must be optimized according to menstrual cycle phase, as endometriotic lesions show cyclical changes in metabolic activity 3
• Metabolically active lesions seen during menstrual phase may show complete resolution during proliferative phase imaging 3
• In one case series, a patient with symptoms but no metabolic activity on initial PET/CT only showed positive findings when repeat imaging was performed during the menstrual phase 3

Why FDG-PET Is Not Clinically Useful

• The American College of Radiology states that FDG-PET/CT has not been studied for the clinical variants of endometriosis and is not part of standard diagnostic algorithms 1
• There is substantial overlap in SUVmax values between endometriotic lesions and low-grade malignancies, creating diagnostic confusion 2
• FDG-PET can interfere with interpretation when performed for other indications (such as cancer staging), as endometriotic lesions may mimic malignancy 2

---

Novel Radiopharmaceutical: Fluoroestradiol F-18 (CERIANNA)

Fluoroestradiol (an estrogen analog PET agent) has shown promise in early clinical trials for detecting endometriosis and represents the most clinically relevant novel agent for this indication. 1

Mechanism and Rationale

• Fluoroestradiol is an estrogen receptor (ER)-targeted PET radiopharmaceutical that binds specifically to estrogen receptors, which are highly expressed in endometriotic tissue 1
• The drug is currently FDA-approved for detecting ER-positive lesions in patients with recurrent or metastatic breast cancer 4
• The recommended dose is 222 MBq (6 mCi) administered intravenously, with imaging performed 80 minutes after injection 4

Advantages Over FDG-PET

• Unlike FDG-PET which relies on variable metabolic activity, fluoroestradiol targets the specific molecular characteristic (estrogen receptor expression) that defines endometriotic tissue 1
• This targeted approach should theoretically provide more consistent detection regardless of menstrual cycle phase, though this has not been definitively proven in endometriosis studies 1

Current Limitations and Considerations

• Early clinical trials show promise, but fluoroestradiol is not yet FDA-approved or validated for endometriosis diagnosis 1
• Before administering fluoroestradiol, drugs that bind to estrogen receptors (SERMs like tamoxifen, SERDs like fulvestrant) must be discontinued for at least 5 biological half-lives to avoid false-negative results 4
• For tamoxifen, this means discontinuation for 8 weeks; for fulvestrant, 28 weeks; and for elacestrant, 11 days 4

---

Current Standard of Care: Why Imaging Alternatives Are Superior

Transvaginal ultrasound (TVUS) and MRI remain the appropriate imaging modalities for endometriosis, not PET scanning. 5

First-Line Imaging Approach

• The American College of Radiology recommends TVUS as the initial imaging modality, with expanded protocol TVUS or MRI pelvis as equally appropriate first-line options 5
• TVUS demonstrates 82.5% sensitivity and 84.6% specificity for endometriosis overall 5
• For endometriomas specifically, TVUS shows 93% sensitivity and 96% specificity, qualifying as both a replacement test and triage test 6

MRI Performance

• MRI without IV contrast shows 90.3% sensitivity and 91% specificity for deep pelvic endometriosis 5
• MRI demonstrates 92.4% sensitivity and 94.6% specificity for intestinal endometriosis 5, 7
• MRI with IV contrast is highly recommended to differentiate endometriomas from ovarian malignancies, given the risk of endometriosis-associated malignancies 1

Why These Modalities Are Superior to PET

• CT pelvis has no role in standard endometriosis diagnosis, and by extension, PET/CT adds no value over dedicated pelvic imaging 1, 5
• TVUS and MRI provide superior anatomic detail for surgical planning, which is the primary clinical need once endometriosis is suspected 5
• These modalities are widely available, less expensive, and do not involve radiation exposure from the radiopharmaceutical 5

---

Critical Clinical Pitfalls

• Do not use any form of PET imaging as initial or routine diagnostic imaging for suspected endometriosis 1, 5
• If endometriotic lesions are incidentally detected on FDG-PET/CT performed for other indications (such as cancer staging), be aware that SUVmax values up to 5.3 can represent benign endometriosis, not malignancy 2
• This is particularly important in postmenopausal women, as FDG-avid endometriosis has been documented in patients up to age 63 years 2
• Negative imaging with any modality does not exclude endometriosis, as all imaging techniques have poor sensitivity for superficial peritoneal disease 5